Related Experiment Video

Updated: Oct 26, 2025

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
02:35

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

1.1K

PF-06409577 Activates AMPK Signaling and Inhibits Osteosarcoma Cell Growth

Yun-Rong Zhu1, Xiang-Yang Zhang2, Qiu-Ping Wu1

  • 1Department of Orthopedics, Affiliated Jiangyin Hospital of Medical College of Southeast University, Jiangyin, China.

Frontiers in Oncology
|August 2, 2021
PubMed

Insights

PF-06409577, an AMP-activated protein kinase (AMPK) activator, effectively inhibits osteosarcoma (OS) cell growth by inducing apoptosis and cell cycle arrest. This novel compound shows promise as a potential therapeutic agent for this bone cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Osteosarcoma (OS) is a primary bone cancer with limited treatment options.
  • AMP-activated protein kinase (AMPK) is a key cellular energy sensor implicated in cancer progression.

Purpose of the Study:

  • To investigate the anti-cancer activity of PF-06409577, a novel AMPK activator, against human osteosarcoma cells.
  • To elucidate the molecular mechanisms underlying PF-06409577's effects in OS.

Main Methods:

  • In vitro studies using established and primary human OS cell lines.
  • In vivo studies in severe combined immunodeficient (SCID) mice xenograft models.
  • Assessment of cell viability, proliferation, apoptosis, cell cycle, AMPK activation, mTORC1 signaling, autophagy, and receptor tyrosine kinase (RTK) expression.

Main Results:

  • PF-06409577 significantly inhibited OS cell viability and proliferation while inducing apoptosis and cell cycle arrest.
  • The compound activated AMPK, inhibited mTORC1, induced autophagy, and downregulated RTKs in OS cells.
  • PF-06409577 demonstrated potent tumor growth inhibition in vivo, with observed AMPK activation and downstream pathway modulation in xenografts.
  • AMPK inactivation abrogated PF-06409577's anti-cancer effects, confirming the critical role of AMPK.

Conclusions:

  • PF-06409577 exhibits significant anti-osteosarcoma activity through AMPK activation.
  • This novel AMPK activator holds potential as a therapeutic strategy for osteosarcoma.
Keywords:
AMPKPF-06409577cell growthosteosarcomasignaling

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.9K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.3K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.7K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
14.4K